US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist
  • 8.680
  • +0.275+3.27%
Close Nov 22 16:00 ET
  • 8.695
  • +0.015+0.18%
Post 20:01 ET
617.36MMarket Cap-5528P/E (TTM)

Altimmune Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-98.62%5K
-16.67%5K
-76.19%5K
726.47%426K
133.64%37K
18,000.00%362K
-25.00%6K
-34.38%21K
-101.54%-68K
-103.36%-110K
Operating revenue
-98.62%5K
-16.67%5K
-76.19%5K
726.47%426K
133.64%37K
18,000.00%362K
-25.00%6K
-34.38%21K
-101.54%-68K
-103.36%-110K
Cost of revenue
Gross profit
Operating expense
8.17%24.77M
48.50%26.75M
23.04%26.8M
-4.26%83.94M
-7.58%21.24M
-7.48%22.9M
-11.71%18.01M
11.52%21.78M
-2.54%87.67M
-4.08%22.98M
Selling and administrative expenses
10.08%4.97M
17.54%5.6M
17.24%5.31M
5.85%18.14M
13.85%4.33M
0.49%4.51M
7.94%4.76M
2.35%4.53M
11.17%17.13M
0.74%3.81M
-General and administrative expense
10.08%4.97M
17.54%5.6M
17.24%5.31M
5.85%18.14M
13.85%4.33M
0.49%4.51M
7.94%4.76M
2.35%4.53M
11.17%17.13M
0.74%3.81M
Research and development costs
7.70%19.8M
59.62%21.16M
24.57%21.49M
-6.72%65.8M
-11.84%16.91M
-9.25%18.39M
-17.13%13.25M
14.20%17.25M
-5.37%70.54M
-4.98%19.18M
Operating profit
-9.88%-24.77M
-48.53%-26.75M
-23.14%-26.79M
4.82%-83.51M
8.18%-21.2M
8.94%-22.54M
11.71%-18.01M
-11.59%-21.76M
-2.57%-87.74M
-11.65%-23.09M
Net non-operating interest income expense
2.64%1.9M
18.99%2.18M
44.78%2.41M
155.63%7.32M
18.84%1.96M
87.56%1.86M
596.96%1.83M
4,163.41%1.67M
1,345.45%2.86M
832.77%1.65M
Non-operating interest income
1.38%1.91M
18.91%2.18M
44.66%2.41M
156.13%7.35M
33.79%1.96M
78.92%1.88M
459.45%1.84M
7,842.86%1.67M
1,313.79%2.87M
1,176.52%1.47M
Non-operating interest expense
-79.31%6K
-50.00%1K
-50.00%1K
337.50%35K
101.09%2K
-54.69%29K
-96.92%2K
-96.77%2K
60.00%8K
-195.16%-183K
Other net income (expense)
28.57%18K
-167.26%-76K
-163.16%-12K
-38,190.63%-12.25M
-5,613.82%-12.4M
-72.00%14K
352.00%113K
-82.73%19K
99.73%-32K
93.58%-217K
Special income (charges)
----
----
----
---12.42M
----
----
----
----
--0
----
-Less:Impairment of capital assets
----
----
----
--12.42M
----
----
----
----
--0
----
Other non- operating income (expenses)
28.57%18K
-167.26%-76K
-163.16%-12K
618.75%166K
109.22%20K
-72.00%14K
352.00%113K
-82.73%19K
91.44%-32K
-167.90%-217K
Income before tax
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.17%-88.45M
-46.08%-31.64M
12.83%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.55%-84.91M
9.33%-21.66M
Income tax
0
-197K
0
Net income
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Net income continuous Operations
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Minority interest income
Net income attributable to the parent company
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Basic earnings per share
17.95%-0.32
-9.37%-0.35
15.00%-0.34
8.29%-1.66
-30.23%-0.56
18.75%-0.39
23.81%-0.32
9.09%-0.4
22.98%-1.81
24.56%-0.43
Diluted earnings per share
17.95%-0.32
-9.37%-0.35
15.00%-0.34
8.29%-1.66
-30.23%-0.56
18.75%-0.39
23.81%-0.32
9.09%-0.4
22.98%-1.81
24.56%-0.43
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue -98.62%5K-16.67%5K-76.19%5K726.47%426K133.64%37K18,000.00%362K-25.00%6K-34.38%21K-101.54%-68K-103.36%-110K
Operating revenue -98.62%5K-16.67%5K-76.19%5K726.47%426K133.64%37K18,000.00%362K-25.00%6K-34.38%21K-101.54%-68K-103.36%-110K
Cost of revenue
Gross profit
Operating expense 8.17%24.77M48.50%26.75M23.04%26.8M-4.26%83.94M-7.58%21.24M-7.48%22.9M-11.71%18.01M11.52%21.78M-2.54%87.67M-4.08%22.98M
Selling and administrative expenses 10.08%4.97M17.54%5.6M17.24%5.31M5.85%18.14M13.85%4.33M0.49%4.51M7.94%4.76M2.35%4.53M11.17%17.13M0.74%3.81M
-General and administrative expense 10.08%4.97M17.54%5.6M17.24%5.31M5.85%18.14M13.85%4.33M0.49%4.51M7.94%4.76M2.35%4.53M11.17%17.13M0.74%3.81M
Research and development costs 7.70%19.8M59.62%21.16M24.57%21.49M-6.72%65.8M-11.84%16.91M-9.25%18.39M-17.13%13.25M14.20%17.25M-5.37%70.54M-4.98%19.18M
Operating profit -9.88%-24.77M-48.53%-26.75M-23.14%-26.79M4.82%-83.51M8.18%-21.2M8.94%-22.54M11.71%-18.01M-11.59%-21.76M-2.57%-87.74M-11.65%-23.09M
Net non-operating interest income expense 2.64%1.9M18.99%2.18M44.78%2.41M155.63%7.32M18.84%1.96M87.56%1.86M596.96%1.83M4,163.41%1.67M1,345.45%2.86M832.77%1.65M
Non-operating interest income 1.38%1.91M18.91%2.18M44.66%2.41M156.13%7.35M33.79%1.96M78.92%1.88M459.45%1.84M7,842.86%1.67M1,313.79%2.87M1,176.52%1.47M
Non-operating interest expense -79.31%6K-50.00%1K-50.00%1K337.50%35K101.09%2K-54.69%29K-96.92%2K-96.77%2K60.00%8K-195.16%-183K
Other net income (expense) 28.57%18K-167.26%-76K-163.16%-12K-38,190.63%-12.25M-5,613.82%-12.4M-72.00%14K352.00%113K-82.73%19K99.73%-32K93.58%-217K
Special income (charges) ---------------12.42M------------------0----
-Less:Impairment of capital assets --------------12.42M------------------0----
Other non- operating income (expenses) 28.57%18K-167.26%-76K-163.16%-12K618.75%166K109.22%20K-72.00%14K352.00%113K-82.73%19K91.44%-32K-167.90%-217K
Income before tax -10.52%-22.85M-53.42%-24.64M-21.52%-24.39M-4.17%-88.45M-46.08%-31.64M12.83%-20.67M20.12%-16.06M-3.31%-20.07M12.55%-84.91M9.33%-21.66M
Income tax 0-197K0
Net income -10.52%-22.85M-53.42%-24.64M-21.52%-24.39M-4.41%-88.45M-46.08%-31.64M12.10%-20.67M20.12%-16.06M-3.31%-20.07M12.75%-84.71M9.33%-21.66M
Net income continuous Operations -10.52%-22.85M-53.42%-24.64M-21.52%-24.39M-4.41%-88.45M-46.08%-31.64M12.10%-20.67M20.12%-16.06M-3.31%-20.07M12.75%-84.71M9.33%-21.66M
Minority interest income
Net income attributable to the parent company -10.52%-22.85M-53.42%-24.64M-21.52%-24.39M-4.41%-88.45M-46.08%-31.64M12.10%-20.67M20.12%-16.06M-3.31%-20.07M12.75%-84.71M9.33%-21.66M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -10.52%-22.85M-53.42%-24.64M-21.52%-24.39M-4.41%-88.45M-46.08%-31.64M12.10%-20.67M20.12%-16.06M-3.31%-20.07M12.75%-84.71M9.33%-21.66M
Basic earnings per share 17.95%-0.32-9.37%-0.3515.00%-0.348.29%-1.66-30.23%-0.5618.75%-0.3923.81%-0.329.09%-0.422.98%-1.8124.56%-0.43
Diluted earnings per share 17.95%-0.32-9.37%-0.3515.00%-0.348.29%-1.66-30.23%-0.5618.75%-0.3923.81%-0.329.09%-0.422.98%-1.8124.56%-0.43
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Weight Loss Drugs
Weight Loss Drugs
Intraday+1.00%